Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

NCT01266265 · clinicaltrials.gov ↗

COMPLETED

Status

1333

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG: inhaled prostacyclin
DRUG: inhaled prostacyclin
DRUG: prostacyclin
DRUG: subcutaneous and intravenous prostacyclin
DRUG: oral ERA
DRUG: oral PDE5 inhibitors

Sponsor

United Therapeutics